
By the time you’re done reading this story, heart disease will have killed nearly 40 people in Europe. The picture elsewhere isn’t much different. The World Health Organization reported earlier this year that more people die from cardiovascular disease than from any other cause.
The grim statistics is what keep scientists like Anja Brau motivated. “Cardiovascular disease isn’t just a European issue, it’s a human issue,” says Brau, director of global cardiac magnetic resonance at GE Healthcare. Brau and her team of cardiac specialists, physicists, engineers and software developers at GE Global Research in Munich are writing algorithms and building other digital tools that take MRI imaging data generated during heart scans and quickly reconstruct it so that doctors can see what’s going on.
Their technology, ViosWorks* can do the job in 10 to 15 minutes, rather than the more typical 45 minutes to an hour. It displays the results in 7 dimensions – 3 in space, 1 in time, and 3 in velocity direction – showing the actual blood flow in the heart as a moving image. This is critical during heart attacks, which deprive the heart of blood and oxygen.
GE Healthcare brought the technology to this year’s meeting of the Radiological Society of North America (RSNA), which is taking place this week in Chicago. RSNA is the world’s largest gathering of radiologists, drawing an expected 60,000 visitors.

Top GIFs: ViosWorks* combines 3D cardiac anatomy, function, and flow in 1 free-breathing, approximate 8 minute scan. It enables visualization of the whole chest and beating heart from any vantage point – any structure, in any plane – simultaneously seeing ventricles contracting and accurately quantifying blood flow. Above: Vector image demonstrates the directional flow of blood in the heart and vessels. Color depicts velocity of blood flow. For example, red may indicate accelerated flow in areas of valvular abnormalities *7 dimensional viewing capabilities of the heart; 3 in space, 1 in time, 3 in velocity direction. Image and GIF credits: GE Healthcare
ViosWorks* can help physicians distinguish scarred or damaged tissue from healthy heart muscle and tell them whether blood is flowing through the heart the way it should be.
Every second counts. Doctors need to assess damage as quickly as possible to administer the right treatment, prevent death, speed recovery and reduce healthcare costs. The CDC Foundation estimates that by 2030, annual direct medical costs associated with cardiovascular diseases will rise to more than $818 billion, while lost productivity costs could exceed $275 billion. For comparison, the U.S., which has the world’s largest defense budget, spends on the military about $600 billion annually.
![ViosANON50-Flow[2] (1)](http://gereports.cdnist.com/wp-content/uploads/2015/12/02092811/ViosANON50-Flow2-1-1024x540.png)
ViosWorks* demonstrates extraordinary resolution, previously unattainable with conventional imaging and post processing technology. Now with Arterys software, large image datasets of the whole chest can be post processed and evaluated in real-time via cloud technology. Image credit GE Healthcare
But it’s not no easy. MRI works by “acquiring” the image of the organ one thin slice of tissue after another – kind of like rebuilding a salami stick from individual slices. However, the procedure can take up to an hour and patients have to remain still. This is doubly difficult when imaging body parts like the heart, which keeps moving.
![Vios02J-Flow[1] (1)](http://gereports.cdnist.com/wp-content/uploads/2015/12/02092811/Vios02J-Flow1-1-1024x540.png)
ViosWorks* delivers a three-dimensional spatial and velocity-encoded dataset at every time point during the cardiac cycle, yielding high resolution, time-resolved images of the beating heart and a measure of the speed and direction of blood flow at each location. Image credit: GE Healthcare
The software doesn’t need a specialized machine and works with existing MRIs. ViosWorks* also has a major knock-on effect on the rest of the cardiac healthcare system, because MRI scanning acts as an important gatekeeper for determining what treatment cardiac patients go on to receive next.
Says Brau: “As exciting and encouraging as these breakthroughs are, they are also just the beginning of what we can achieve.”
*Not yet commercially available